Form 4: Apyx Medical Director Wendy Levine Receives Stock Options

Director Wendy Levine was granted 50,000 stock options in Apyx Medical Corporation as part of an equity incentive.

Summary

• Director Wendy Levine received a grant of 50,000 stock options for Apyx Medical Corporation common stock.
• The options have an exercise price of $4.65 per share.
• The grant date for these options is June 11, 2026.
• The options vest ratably over a 12-month period, becoming fully exercisable on June 11, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility could impact the value of the options and the incentive alignment.

Future Outlook

The options vest over a one-year period, indicating a retention and performance incentive structure for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The 12-month vesting schedule is a standard practice for director equity compensation in the medical device sector.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on a monthly basis over the next 12 months.

Key Dates

Keywords

Apyx Medical, APYX, Form 4, Insider Trading, Stock Options, Director Compensation